TruScreen Group Limited Ordinary Shares
TRU.NZXHealth Care
TruScreen's development began in the late 1980s under the guidance of leading medical academics from Sydney University. TruScreen offers the latest technology in cervical screening, providing real-time, accurate detection of pre-cancerous and cancerous cervical cells to help improve the health and wellbeing of women around the world. Professor Coppleson, an international leader in colposcopy and cervical cancer, sought to establish objective technology that could improve on the conventional Pap test, which has limitations in population based screening due to its subjective nature and its need of laboratory facilities and qualified personnel. Dr. Reid believed that it should be possible to distinguish between normal and abnormal tissue by measuring changes in physical properties, such as electrical potential. After almost 15 years of intensive R&D, the TruScreen 'Opto Electrical' Technology for the detection of cancerous cells is now being made commercially available to global markets. As the TruScreen technology is at the forefront of the development of objective opto-electric tissue differentiation it enjoys significant patent protection which is of great interest throughout the globe. Following the restructuring of the business, TruScreen Pty Ltd, a subsidiary company of TruScreen Group Ltd (NZ), was formed in October 2013 to hold all TruScreen assets, including IP, and to act as the operations heart of the TruScreen business. The board and executive team combine experience and commercial ideas and strategies which we believe are both essential to and sufficient for the success of TruScreen globally. TruScreen is a compliance listing there will be no new shares issued upon listing. TruScreen is expected to commence trading on the NZX Alternative Board on 12 November 2014.
Market Data
$0.017
+0.1%$17.1M
-5.7x
$-0.003
0.00%
+0.0%
Latest Earnings
Truscreen Annual Report 31 March 2026
29 June 2026
TruScreen Group Limited reported FY2026 (year ending 31 March 2026) product sales growth of 42% year-on-year to NZ$2.43M, with total revenue up 29% to NZ$2.83M, while net loss remained relatively flat at NZ$2.25M. The company significantly expanded its geographic footprint with first sales in India and Indonesia, launched a landmark 260,000-woman screening programme in Vietnam, and had a landmark COGA clinical trial published validating TruScreen as a superior primary cervical cancer screening tool. Cash position improved materially to NZ$1.46M (up 300%) following a NZ$4M capital raise in May 2025, and post-period the company submitted three proposals to UNITAID covering 14 high-burden countries with potential revenue of up to US$18.4M. Key points: Product sales grew 42% YOY to NZ$2.43M with geographic diversification — China's share reduced from 87.6% to 61.3% as new markets including India and Indonesia contributed first sales; Cash and cash equivalents surged 300% to NZ$1.46M following a NZ$4M capital raise in May 2025; Landmark COGA multicentre trial (14,982 women, 64 hospitals, 9 provinces) published in BMC Cancer confirmed TruScreen as superior primary cervical cancer screening tool with highest AUC for CIN2+ and CIN3+
Recent Announcements
ASM Date and Director Nominations
TruScreen Group Limited has announced its Annual Shareholders' Meeting will be held on Tuesday, 1 September 2026, with a director nominations period open until Friday, 31 July 2026. Shareholders can submit director nominations to Chief Financial Officer Guy Robertson at guyrobertson@truscreen.com.
TRU – Waiver from NZX Listing Rule 4.19.1
NZ RegCo granted TruScreen Group Limited (TRU) a waiver from NZX Listing Rule 4.19.1, allowing the company to delay allotment of approximately 22.2 million oversubscribed shares from its Rights Issue beyond the standard 10 business day requirement until after shareholder approval is obtained at a shareholder meeting on 31 July 2026.
SPH Notice - Peter, Joanna, Anatole, Raphael
Peter, Joanna, Anatole, Raphael changed substantial holding from 4.05% to 6.94%.
TRU – Waivers from NZX Listing Rules 4.19.1 and 7.8.5(b)
NZ RegCo granted TruScreen Group Limited (TRU) waivers from NZX Listing Rules 4.19.1 and 7.8.5(b) to permit deferred allotment of approximately 20 million oversubscribed placement shares (Tranche 2) until after shareholder approval on 31 July 2026, and to issue 22.5 million director options without an independent appraisal report.
Notice of Special Meeting
Truscreen Group Limited is holding a special shareholder meeting on 31 July 2026 to approve multiple capital-raising initiatives, including ratification of a prior share placement (109,999,995 shares at NZ$0.014), approval of additional placement shares and options, broker options, director options (22,500,000 to be issued to four directors), shares for services, and a rights offer (22,188,094 shares at NZ$0.013), with total anticipated dilution of 26.31% for non-participating shareholders.
Corporate Action Notice
Truscreen Group Limited issued 149,464,986 ordinary shares on 30 June 2026 at NZ$0.013/A$0.011 per share through a Renounceable Rights Issue, representing 17.4% of the total class, bringing total shares outstanding to 1,006,790,307.
Change In Substantial Shareholder Notice
Ven Capital Pty Ltd increased its voting power in Truscreen Group Limited from 5.42% to 7.02% (60,220,780 shares) through a series of on-market share purchases between June 1-15, 2026, totaling approximately $316,586 in consideration.
Initial Substantial Shareholder Notice
Ven Capital Pty Ltd became a substantial shareholder in TruScreen Group Limited on 1 June 2026, acquiring 40,492,982 ordinary shares (5.42% voting power) through on-market purchases and a placement totaling approximately $541,467.
Truscreen Annual Report 31 March 2026
TruScreen Group Limited reported FY2026 (year ending 31 March 2026) product sales growth of 42% year-on-year to NZ$2.43M, with total revenue up 29% to NZ$2.83M, while net loss remained relatively flat at NZ$2.25M. The company significantly expanded its geographic footprint with first sales in India and Indonesia, launched a landmark 260,000-woman screening programme in Vietnam, and had a landmark COGA clinical trial published validating TruScreen as a superior primary cervical cancer screening tool. Cash position improved materially to NZ$1.46M (up 300%) following a NZ$4M capital raise in May 2025, and post-period the company submitted three proposals to UNITAID covering 14 high-burden countries with potential revenue of up to US$18.4M. Key points: Product sales grew 42% YOY to NZ$2.43M with geographic diversification — China's share reduced from 87.6% to 61.3% as new markets including India and Indonesia contributed first sales; Cash and cash equivalents surged 300% to NZ$1.46M following a NZ$4M capital raise in May 2025; Landmark COGA multicentre trial (14,982 women, 64 hospitals, 9 provinces) published in BMC Cancer confirmed TruScreen as superior primary cervical cancer screening tool with highest AUC for CIN2+ and CIN3+
Rights Issue Completes Substantially Oversubscribed
TruScreen Group Limited (NZX/ASX:TRU) completed a substantially oversubscribed rights issue, receiving applications for 171.7 million shares against an offer of 149.5 million shares (15% oversubscription). The company will allot 80.6 million rights issue shares and 68.8 million shortfall shares on 30 June 2026 at NZ$0.013/share, with an additional 22.2 million shares subject to shareholder approval at a general meeting expected 28 July 2026, bringing total capital raised to approximately NZ$4 million.
Get real-time alerts for TRU
Receive AI-powered earnings summaries and instant notifications when TruScreen Group Limited Ordinary Shares releases results.
Register Free